Insilico Medicine Inc. has identified sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers that are potentially useful for the treatment of pain.
Researchers from Convalife Pharmaceuticals Co. Ltd. and Zhejiang Convalife Pharmaceutical Co. Ltd. have described dual CDK4/cyclin D1 and cyclin-dependent kinase 9 (CDK9) inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Shanghai Pharmaceuticals Holding Co. Ltd. has reported interleukin-17A (IL-17A) inhibitors that are potentially useful for the treatment of psoriasis, rheumatoid arthritis, spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis and uveitis.
Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. has disclosed heterocyclic compounds and their antibody-drug conjugates reported to be useful for the treatment of cancer.
Alturos Therapeutics BV has advanced its lead candidate, ALT-0135, into IND-enabling studies. Alturos is targeting the earliest toxic triggers in Alzheimer’s disease, particularly protein oligomers that drive synaptic loss and neuronal death.
Researchers from Rivus Pharmaceuticals Inc. presented preclinical efficacy data on RV‑202, a novel oral mitochondrial uncoupler with activity attributed to adenine nucleotide translocase (ANT) activation, in models of obesity.
Due to the availability of drugs targeting histone acetylation and associated reader proteins, the equilibrium of histone acetylation and deacetylation has attracted attention in multiple myeloma as a potential therapeutic target. Therefore, the identification of novel predictive biomarkers for multiple myeloma patient selection for epigenetic therapies is urgently needed.
Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies achieve objective response rates of 40%-50%, while immunotherapy has not been established.
Saniona AB has presented preclinical data and its clinical development strategy for its lead clinical candidate, SAN-2668, which is a GABA-A receptor positive allosteric modulator under development for the treatment of severe pediatric epilepsies.
Cenna Biosciences Inc. has obtained IND clearance from the FDA for 8M2D, a first-in-class peptide for the treatment of Alzheimer’s disease. A phase Ia/Ib trial of 8M2D in healthy volunteers and patients with early Alzheimer’s disease is expected to begin dosing late this year.
RSS
